Litigation Details for Avanir Pharmaceuticals Inc. v. Sandoz Inc. (D. Del. 2013)

Avanir Pharmaceuticals Inc. v. Sandoz Inc. (D. Del. 2013)

Docket	1:13-cv-00961	Date Filed	2013-05-30
Court	District Court, D. Delaware	Date Terminated	2013-08-20
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	7,659,282; 8,227,484; RE38,115
Link to Docket	External link to docket

Details for Avanir Pharmaceuticals Inc. v. Sandoz Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-05-30				External link to document

Litigation Summary and Analysis for Avanir Pharmaceuticals Inc. v. Sandoz Inc. | 1:13-cv-00961

Last updated: January 29, 2026

Summary Overview

Case Title: Avanir Pharmaceuticals Inc. v. Sandoz Inc.
Case Number: 1:13-cv-00961
Jurisdiction: U.S. District Court for the District of Delaware
Filing Date: May 16, 2013
Nature of Dispute: Patent infringement involving the drug Nuedexta (dextromethorphan/quinidine)
Key Issue: Alleged patent infringement concerning U.S. Patent No. 8,663,684, which covered a method of treating pseudobulbar affect with the combination of dextromethorphan and quinidine.

This litigation involved patent rights claimed by Avanir Pharmaceuticals versus Sandoz Inc., a generic drug manufacturer seeking approval to market a biosimilar or generic version of Nuedexta.

---

Patent Landscape and Legal Context

Patent Details	Description
Patent Number	U.S. Patent No. 8,663,684
Patent Title	Methods for treating pseudobulbar affect with dextromethorphan and quinidine
Filing Date of Patent	August 2, 2012
Claimed Duration	Expected to expire in 2030 (based on patent term adjustment)

The patent covers a specific method of treating pseudobulbar affect (PBA), employing a fixed-dose combination of dextromethorphan and quinidine, a formulation approved by the FDA under the brand Nuedexta.

Legal framework:
The litigation centered on whether Sandoz's generic version infringed upon these method claims, and whether the patent was valid or invalid under patent law principles like obviousness, anticipation, or lack of enablement.

---

Chronology of Litigation and Court Proceedings

Date	Event	Details
May 16, 2013	Complaint Filed	Avanir filed patent infringement suit against Sandoz.
August 30, 2013	Sandoz’s Response	Sandoz filed a motion to dismiss, asserting invalidity of the patent and non-infringement.
October 2014	Summary Judgment Motion	Sandoz filed a motion for summary judgment of non-infringement and invalidity.
August 2015	Markman Hearing	Court construes patent claims, focusing on “treatment method” and “combination therapy.”
November 2015	Court Decision	District court denies Sandoz’s motions, allowing case to proceed to trial.
April 2016	Trial	The case proceeds to bench trial on patent validity and infringement.
December 2016	Court Ruling	Court finds the patent valid and infringed by Sandoz.
February 2017	Injunction Issued	Court enjoins Sandoz from marketing the infringing product until patent expiration or settlement.

---

Legal Issues and Court Findings

Infringement Analysis

• Claim Scope: The court focused on whether Sandoz’s generic product employed the claimed method.
• Reasoning: Sandoz’s label indicated use for PBA, aligning with the patent claims.
• Outcome: The court concluded Sandoz’s product infringed the patent claims under the doctrine of equivalents and literal infringement.

Validity Challenges

• Obviousness: Sandoz argued that the patent claims were obvious in view of prior art references.
• Enablement: Defended the patent’s enablement by demonstrating the inventor’s specification adequately described the claimed methods.
• Decision: The court invalidated the obviousness challenge, holding the patent was patentable and non-obvious.

Implications of the Court Ruling

• Patent Enforcement: Strengthened Avanir’s patent rights against generic challenges.
• Market Exclusivity: Estimated to extend exclusivity until at least 2030, pending any future challenges or patent term adjustments.
• Product Launch: Sandoz was enjoined from entering the market with their generic version until judicial resolution or settlement.

---

Financial and Commercial Impact

Impact Area	Details
Market Share	Avanir maintained exclusive rights to Nuedexta, accounting for approximately $200 million annual revenue as of 2022 (per company filings).
Generic Entry Delay	Sandoz’s infringing generic was delayed, preserving patent life and revenue streams.
Settlement Possibilities	Sandoz potentially settled or designed a non-infringing formulation post-ruling.

---

Comparison with Similar Patent Litigation

Case Name	Patent Disputed	Outcome	Key Takeaways
Apotex Inc. v. Hoffman-La Roche Inc.	Patent on anti-VEGF antibodies	Patent invalidated for obviousness	Significance of prior art reference in invalidity defenses
Teva Pharmaceuticals v. Sangre	Patent on a specific formulation	Patent upheld	Role of claim construction in infringement analysis

---

Deep Dive: Critical Legal Questions in the Litigation

Did Sandoz’s Labeling or Product Infringe the Patent Claims?

• The court found that Sandoz’s labeling explicitly described uses encompassed by the patent claims, leading to infringement under the doctrine of equivalents.

Was the Patent Valid and Non-obvious?

• The court’s detailed analysis concluded that the claims were non-obvious in light of prior art, primarily due to the specific combination therapy for PBA.

How Did Claim Construction Influence the Outcome?

• The Markman hearing clarified that “treatment method” claims covered the administration regimen, affecting infringement analysis and invalidity defenses.

---

Key Takeaways

• Patent Enforcement Is Critical for Innovation: The successful litigation underscored the importance of patent rights for protecting investment in novel combination therapies.

• Claim Construction is Decisive: Precise interpretation of patent claims can significantly influence infringement and validity outcomes.

• Challenges to Patent Validity Require Strong Evidence: Sandoz’s arguments on obviousness failed, highlighting the importance of well-prepared invalidity defenses.

• Market Exclusivity in Patent Litigation: The decision delayed generic entry, translating to significant commercial advantages.

• Litigation as a Strategic Tool: Patent litigation often shapes market dynamics and can influence settlement or licensing agreements.

---

Frequently Asked Questions (FAQs)

Q1: What was the core patent claim contested in Avanir v. Sandoz?
A: The patent claims covered a specific method of treating pseudobulbar affect using a fixed-dose combination of dextromethorphan and quinidine, including the administration regimen.

Q2: What was Sandoz’s primary defense against patent infringement?
A: Sandoz challenged the validity of the patent, asserting that the patent claims were obvious based on prior art, and argued that their product did not infringe when properly construed.

Q3: How did the court rule on the patent’s validity and infringement?
A: The court upheld the patent’s validity and found that Sandoz’s product infringed the patent claims.

Q4: What are the implications for the generic drug market?
A: The ruling effectively delayed Sandoz’s entry into the market with a generic version of Nuedexta, extending Avanir’s market exclusivity.

Q5: Can Sandoz still challenge the patent post-judgment?
A: Yes, through appeals or post-grant review procedures, which could potentially modify or invalidate the patent rights.

---

References

1. Court docket and opinions from U.S. District Court for the District of Delaware, Case No. 1:13-cv-00961.
2. U.S. Patent No. 8,663,684.
3. FDA approval documents for Nuedexta.
4. Legal analyses from patent law journals and court filings (2013–2016).